Loading...
XSHG
600085
Market cap6.96bUSD
Jun 20, Last price  
35.99CNY
1D
-0.95%
1Q
-1.54%
Jan 2017
15.95%
Name

Beijing Tongrentang Co Ltd

Chart & Performance

D1W1MN
P/E
32.34
P/S
2.65
EPS
1.11
Div Yield, %
2.75%
Shrs. gr., 5y
—
Rev. gr., 5y
6.97%
Revenues
18.60b
+4.12%
2,605,732,4362,396,505,1762,702,850,9392,939,049,5113,250,219,8843,824,446,1416,108,383,7117,504,031,9778,714,647,4019,685,867,52210,808,761,22912,090,740,12213,375,966,34414,208,636,44613,277,123,19912,825,879,05014,603,100,73915,372,423,36317,860,891,45618,597,281,604
Net income
1.53b
-8.54%
301,231,159156,021,181232,891,142258,946,471285,610,659343,233,607438,066,654570,056,218656,013,728763,669,171875,179,501933,165,3911,017,381,5491,134,283,8471,561,601,3281,616,363,3051,890,760,4592,199,390,8111,668,834,5091,526,274,925
CFO
761m
-59.29%
191,538,984384,559,921121,020,805422,789,931627,689,915492,043,803544,905,320873,968,414676,398,667696,013,987832,472,8451,045,766,4821,448,915,1621,928,378,9942,273,710,5392,174,631,6633,426,414,5633,094,296,2841,869,491,851760,985,272
Dividend
Oct 10, 20240.5 CNY/sh

Profile

Beijing Tongrentang Co., Ltd engages in the scientific research, production, sale, and distribution of Chinese medicines in China and internationally. It covers product formulations, such as pills, powders, wines and capsules, oral liquids, and dripping pills with the original powder preparation in the areas of cardiovascular, cerebrovascular, and gynecological diseases, as well as anti-depressive new drugs. The company sells its products under the brand names of Angong Niuhuang series, Tongren Niuhuang Qingxin series, Tongren Dahuoluo series, Yufeng Ningxin dripping pills, Hemiplegia recovery pills, etc. The company is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.
URL
https://gf.tongrentang.com/
IPO date
Jun 25, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
18,597,282
4.12%
17,860,891
16.19%
15,372,423
5.27%
Cost of revenue
12,446,700
11,253,532
11,444,700
Unusual Expense (Income)
NOPBT
6,150,582
6,607,360
3,927,724
NOPBT Margin
33.07%
36.99%
25.55%
Operating Taxes
525,046
497,429
517,547
Tax Rate
8.54%
7.53%
13.18%
NOPAT
5,625,536
6,109,931
3,410,177
Net income
1,526,275
-8.54%
1,668,835
-24.12%
2,199,391
16.32%
Dividends
(483,095)
(397,726)
Dividend yield
0.66%
0.65%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
187,721
93,025
795,422
Long-term debt
3,762,090
3,561,244
2,943,340
Deferred revenue
169,386
157,568
153,956
Other long-term liabilities
5,859
167,097
9,475
Net debt
(6,901,674)
(8,503,430)
(7,913,355)
Cash flow
Cash from operating activities
760,985
1,869,492
3,094,296
CAPEX
(324,515)
Cash from investing activities
(313,165)
Cash from financing activities
(1,438,031)
FCF
3,695,396
5,059,702
3,721,715
Balance
Cash
10,756,681
12,132,267
11,624,415
Long term investments
94,804
25,432
27,702
Excess cash
9,921,621
11,264,655
10,883,496
Stockholders' equity
17,462,324
17,052,504
16,630,984
Invested Capital
13,846,208
11,748,071
10,193,632
ROIC
43.96%
55.69%
32.90%
ROCE
25.86%
28.70%
18.63%
EV
Common stock shares outstanding
1,371,470
1,370,973
Price
40.59
-24.41%
53.70
20.19%
44.68
-0.67%
Market cap
73,647,953
20.23%
61,255,065
-0.70%
EV
72,343,617
59,988,502
EBITDA
7,122,037
7,522,632
4,813,316
EV/EBITDA
9.62
12.46
Interest
133,760
119,676
111,398
Interest/NOPBT
2.17%
1.81%
2.84%